diagnostic criteria for a current major depressive episode will be recruited via the research arm of a not-for-profit clinical and research unit in Australia. The minimum sample size for each group (alpha set at 0.05, power at .80) was identified as 29, but at least 10% more will be recruited to hedge against expected attrition. We will measure the impact of CBM on primary measures of depressive symptoms (BDI-II, PHQ9) and interpretive bias (AST-D),
and on a secondary measure of psychological distress (K10) following the 1 week CBM intervention. Secondary outcome measures of psychological distress (K10), as well as disability (WHODAS), repetitive negative thinking (RTQ), and anxiety (STAI) will be evaluated following completion of the 11-week combined intervention, in addition to the BDI-II and PHQ9. Intent-to-treat (ITT) marginal and mixed effect models using restricted maximum likelihood (REML) estimation will be used to evaluate the primary hypotheses.
Clinically significant change will be defined as high-end state functioning (a BDI-II score < 14) combined with a total score reduction greater than the reliable change index score (RCI).
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Background and Rationale
Depression is a global health problem, estimated as the leading cause of burden of all diseases in middle and high-income countries, and to become the leading cause worldwide by 2030 (1) . The limitations in efficacy and accessibility of current treatments for depression have led to increasing recognition of the need for treatment innovation, such as development of novel, easier to access, and more cost-effective psychological therapies (2) . Cognitive science provides one promising avenue for such work. Cognitive models propose that biases in the processing of emotional information contribute to the onset, maintenance, and recurrence of depression (3). These biases have traditionally been targeted via psychological therapies such as cognitive behaviour therapy (CBT), which has established efficacy for depression (4) . However, research has begun to demonstrate more recently that simple computerised procedures, known as cognitive bias modification (CBM; (5)) may be used to selectively target biases and lead to significant reductions in symptoms related to depressed mood and depression (6-9).
In the CBM paradigm most commonly used for depression (an imagery focussed form of interpretation bias training), participants listen to descriptions of everyday situations that start ambiguous as to their potential outcome, but which are consistently resolved positively.
While listening to the descriptions, participants are required to imagine themselves in the situation described, through their own eyes (in a 'field perspective'), as if actively involved in the situation. By repeatedly constraining participants to imagine positive (rather than negative) outcomes for the hundreds of ambiguous situations encountered in the training, this imagery CBM aims to train a bias to automatically imagine positive resolutions for novel ambiguous situations encountered in daily life. Depressed individuals may struggle to imagine positive future events (10, 11) and tend to interpret ambiguous information negatively rather than positively -a negative interpretation bias (12) , and thus the repeated The preliminary findings investigating imagery CBM in depression suggest that it may have therapeutic benefit when delivered as a standalone intervention (6, 7).
Alternatively, as experts in the field of CBM research (14) have noted that since CBM procedures lend themselves to being delivered remotely, CBM procedures could potentially be combined with existing evidence-based internet programs such as internet cognitive behavioural therapy (iCBT) to produce optimal therapeutic outcomes. However, combining two interventions targeting similar cognitive processes into a single treatment package may pose unique difficulties as they could potentially interact in a way that cancels out their individual therapeutic benefits (15) . Whether it is possible to successfully combine the imagery CBM with iCBT into an efficacious treatment for depression is therefore an important question to evaluate.
In the first trial to evaluate this proposal we (16) also demonstrated that the effects of the program were not simply due to non-specific effects such as repeatedly engaging in a task or distraction. Further, the study suggested that it was the consistently positive resolution of the imagined scenarios (for positive interpretation bias acquisition), rather than generation of imagery per se, that accounted for the effects of the intervention. To investigate the additive benefit of positive imagery CBM when delivered prior to iCBT, compared to iCBT alone, using an active control for the CBM component of the intervention would similarly allow us to demonstrate that the any additional effects of the positive imagery CBM were not simply due to non-specific factors, or any potential "active" components shared with the control condition.
The current SPIRIT-compliant (17) following the 1-week CBM intervention.
Trial Design
The trial is a randomised controlled superiority trial with two parallel arms using a 1:1 allocation ratio.
Hypotheses
Based on previous findings (7, 16) we predict that patients randomised to positive imagery CBM will evidence significant reductions on primary measures of depressive symptoms (BDI-II, PHQ9) and interpretive bias (AST-D), and on a secondary measure of psychological distress (K10) following the 1 week CBM intervention. We predict superiority (as indexed by hedges g between-group comparisons) of positive imagery CBM over CBM Control on these measures. Further, we predict that patients randomised to the combined intervention group (CBM + iCBT) will evidence significant reductions in the measures of depression (BDI-II, PHQ9) and psychological distress (K10), as well as disability (WHODAS), repetitive negative thinking (RTQ), and anxiety (STAI) following completion of the combined program. We further predict that benefits will be maintained at 3-month follow-up. We will also investigate the potential impact of baseline variables on treatment adherence, ratings of acceptability, and therapeutic outcomes.
Methods

Study Setting
The 
Participants and Recruitment
Power calculations were informed by calculation of effect size data from Lang et al.,
(2012) providing a between-group effect corresponding to Hedges's g of .66. The minimum sample size for each group (alpha set at 0.05, power at .80) was identified as 29, but at least 10% more will be recruited to hedge against expected attrition. Participants will be recruited via the research arm of a not-for-profit clinical and research unit affiliated with St. Vincent's
Hospital and the University of New South Wales, Australia. Applicants first complete online (18)) to determine whether they meet diagnostic criteria for a major depressive episode. All interviews will be conducted by a registered Psychologist trained in administration of the diagnostic interview. Applicants who satisfy all inclusion criteria will be informed of the study design and will complete an electronic informed consent prior to being enrolled in the trial. All participants are informed in writing that they have right to withdraw from the study at any time without jeopardising their relationship with St. Vincent's
Hospital or the University of New South Wales.
Randomisation
Eligible participants accepted into the program will be randomised based on an allocation sequence generated by an independent person not involved in the study via a true randomisation process (www.random.org). Numbers corresponding to treatment group (1 or 2) will be placed in sealed opaque envelopes with the sequential order number written on each envelope to ensure participants are allocated according to the pre-determined sequence. Patient Health Questionnaire (PHQ-9; (26)). The PHQ-9 is a self-report questionnaire corresponding to the DSM-IV diagnostic criteria for major depressive disorder.
Each item is rated in frequency on a 4-point (0 = not at all, 3 = nearly every day) scale. Total scores range from 0 to 27 with higher scores reflecting higher levels of psychopathology. A PHQ-9 score of ≥10 is used as a clinical cut-off for probable DSM-IV diagnosis of MDD (27). The PHQ-9 demonstrates good psychometric properties and has been used extensively to measure treatment outcomes during internet CBT interventions targeting depression and anxiety (16, 28).
Kessler-10 Psychological Distress Scale (K10; (29) ). The K10 consists of 10 items ranked on a five point scale designed to measure non-specific psychological distress. For the current study, the time-frame was modified to assess psychological distress in the past 2 The PHQ9, BDI-II, and K10 will be administered at baseline, following the 1-week CBM intervention, following the combined intervention, and at 3-month follow-up. 
Ambiguous Scenarios Test-Depression
Diagnostic Status. Change in diagnostic status will be indexed using the MINI (18).
Depression Module administered at baseline and 3-month follow-up.
Secondary Outcome Measures
The following secondary measures will be collected at baseline, following completion of the combined intervention, and at 30month follow-up.
World Health Organization Disability Assessment Schedule-II (WHODAS-II).
The WHODAS-II contains 12 items designed to measure disability and activity limitation in the past 30 days in a variety of domains: 1) understanding and communicating, 2) self-care, 3) mobility, 4) interpersonal relationships, 5) work and household roles, and 6) community and civic roles. Each of these domains loads significantly onto one underlying latent factor of global disability (32) . Scores range from 0 to 60, with higher scores indicating greater disability. The WHODAS-II demonstrates strong psychometric properties (33). 
Comorbid Diagnostic Status. Comorbid Generalised Anxiety Disorder (GAD) and
Social Phobia (SP) status will be indexed by the MINI GAD and SP modules conducted at baseline and 3 month follow-up. 
Treatment Expectancy and Outcomes
Additional Measures:
The Prospective Imagery Task (PIT; (38, 39) ) was used to measure imagery for 10 positive and 10 negative prospective events. As in Holmes et al. (38) subjects were asked to rate the vividness of prospective positive events (e.g., "You will have lots of energy and enthusiasm") or negative events (e.g., "Someone close to you will reject you") on a 5-point scale (1 = no image at all; 5 = very vivid). The PIT will be administered at baseline as a potential moderator of the CBM intervention and to check that both groups are balanced on imagery ability at baseline.
Clinical Perfectionism Questionnaire (CPQ; (40)). The CPQ is a12-item self-report measure of clinical perfectionism, or the striving for high personal standards in combination with negative self-evaluations about the impact of not meeting these standards (41) .
Respondents rate the extent to which each of the 12 items describes them over the past month . The SoCT-P will be administered following completion of the combined intervention. The SoCT-P will be included as a potential moderator of treatment response during iCBT.
Data Collection and Management
Data for the primary and secondary outcome questionnaires are collected via the Virtual Clinic system software and Key Survey software licensed by UNSW. All information To promote participant retention, participants are reminded that data collection is an important aspect of research and enables the research team to track their progress and to evaluate the program. Participants are offered one entry into a draw for a gift card valued at $100 AUD in exchange for completion of the 3-month follow-up questionnaires. All data will be extracted from the CBM and iCBT software servers in the form of either an SPSS output file or an Excel compatible file to be transferred to SPSS by a member of the research team.
All data will be stored on a secure Virtual Clinic server.
Participants are informed in writing that the research team will plan to publish the results of the trial in peer-reviewed scientific publications and presentations. Participants are informed that in any publication or presentation, information will be provided in such a way to maintain anonymity. All members of the research team who provide intellectual input to the trial design, execution, or write-up will be acknowledged as an Author on any publications. Participants will be sent (via email) a written summary of the results in lay terms following completion of the trial study phase.
Statistical Methods
Significance testing of group differences regarding demographic data and pretreatment measurements will be conducted using ANOVA and χ2 where the variables consist of nominal data. Intent-to-treat (ITT) mixed models using restricted maximum likelihood (REML) estimation will be used to account for missing data due to participant drop-outs without assuming that the last measurement is stable (the last observation carried forward assumption; (44) . REML models are appropriate for RCTs with multiple time points and prepost only designs (45) . The assumption that data is Missing at Random (MAR) will be evaluated using binary logistic regression to predict drop-outs (0 = no drop-out, 1 = drop-out)
and by comparing these two groups on baseline measures. Significant effects will be followed up with pairwise contrasts comparing pre-treatment to post-treatment scores. Complete-case analyses of the primary hypotheses using data from participants who complete all 7 sessions of the CBM program will also be conducted. The effect of potential treatment moderators will be evaluated by including baseline variables of interest as a covariate and interaction term in separate mixed models analyses. Analyses will be performed in SPSS version 21.
Effect sizes will be calculated between groups (Hedges g) and within groups (Cohen's d, adjusting for the repeated measures correlation) using the pooled standard deviation and adjusted for sample size. Consistent with previous research (46), clinically significant change will be defined as high-end state functioning (a BDI-II score < 14) combined with a total score reduction greater than the reliable change index score (RCI) of 7.16 (47) Due to the high rate of comorbid anxiety disorders, clinically significant change will also calculated for the STAI-T based on a RCI of 7.86 in combination with a final score below the recommended cut-score of 45.7 (48). Estimates of indirect effects will be generated using bootstrapping analysis and PROCESS (49).
Monitoring
The clinical trials manager of CRUfAD and a member of the research team will oversee data collection and monitoring. An interim analysis will only be conducted to check that the planned number of participants have been retained in the trial following enrolment. Any adverse events will be reported to the head of CRUfAD and to the HREC of St.
Vincent's Hospital, the responsible body for initiating a clinical trial audit.
Ethics and Dissemination
Discussion
The current randomised controlled trial will provide a test of the effectiveness of a combined imagery CBM and iCBT intervention in the treatment of current major depression.
It will also attempt to replicate the initial successful application of imagery CBM delivered via the internet without face-to-face contact, and establish whether this is superior to a closely-matched control version when delivered in this manner.
The choice of control condition is a challenge and raises questions. For example, whether to control for bias, imagery, activity such as engaging in repeated practise of a computer task, or some other aspect. The main aim of the current study is to investigate the efficacy of the combined imagery CBM and iCBT intervention, and the choice of control CBM is a pragmatic choice based on a previous study (7) and experimental work (50), albeit in shorter time frames. However, we note that both the positive imagery and this control condition involve generating mental images. It may be that this mental imagery practice in itself (regardless of imagery valence) could enhance the subsequent effects of iCBT, for example by facilitating access to alternative meanings, or facilitating the kind of (imagerybased) future simulation involved in planning (51), e.g. activity scheduling. If this is the case 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
